Suggestions
George Bashirians
CDx/Dx Consultant to Diagnostics and Biotechnology/Pharmaceutical Companies
George Bashirians is a highly skilled and results-driven professional with over 30 years of experience in the Diagnostics and Pharmaceutical industries, holding a Six Sigma Black Belt Certification.
He possesses comprehensive expertise in the full Diagnostics Product Life Cycle, from Biomarker discovery through to assay commercialization, having successfully developed and launched eight IVD products, five Companion Diagnostic tests, and one Complementary Diagnostics test.
With a background in leading both internal and external technical and cross-functional teams, George has a solid track record in fostering external collaborations and overseeing various aspects of collaborations such as technology assessment, partner selection, and project governance.
His working experience spans across areas like Cardiovascular Disease, Infectious Diseases, Neuroscience, Oncology, Rare Disease, and Gene Therapy, specializing in Companion Diagnostics, Complementary Diagnostics, and fostering collaborations between Pharmaceutical and Diagnostics industries.
George pursued his PhD in Chemistry at City, University of London, and has held significant positions in renowned organizations, including being the Founder and Principal at CompanionDx Consulting, Senior Director and Director at Pfizer, Senior Manager of Product Development, Research Fellow, and Principal Scientist at Ortho Clinical Diagnostics.
Highlights
I am thrilled to announce that after 11 years at Pfizer, I am moving on and starting an independent consultancy company.
Looking back at my tenure as Diagnostics Lead for non-oncology at Pfizer, I learned and grew as a professional and I believe, that I made significant contributions to the implementation of Precision Medicine and Diagnostics strategies for non-oncology assets. I am grateful for the opportunity to have worked alongside many highly talented and dedicated colleagues at Pfizer as well as external partners on a number of impactful projects, providing Dx/CDx support to bring novel treatments to patients.
I would like to thank Pfizer leadership, my Pfizer as well as my external colleagues for their trust, support, and partnership. I am proud of what we were able to achieve together.
Looking forward, I am very excited to set up my own independent consultancy company where I will be able to share the experience gained over 30 years in the Diagnostics and Biotech/Pharma industries with a wider set of clients.
My consultancy company is simply called Companion Dx Consulting LLC. Please check my website and reach out. I would love to hear from you.
https://lnkd.in/em-QM4WS
I look forward to reconnecting with you for new partnerships and collaborations.
Happy to share that a review article I co-authored with my esteemed colleagues titled "Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy" has been published in the March issue of Molecular Therapy.
https://lnkd.in/eqFf5vxV
